Stock listing
INMB Stock Price, News, Filings & Events — Inmune Bio Inc.
Selected listing: INMB · NASDAQ · USD · US
This page tracks Inmune Bio Inc.'s INMB:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following INMB:NASDAQ. INMB:NASDAQ is the stock-level entry point for investors researching Inmune Bio Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Inmune Bio Inc. is a public company traded under the ticker INMB in the American market. The company has a market capitalization of approximately $43.1 million. Inmune Bio focuses on developing innovative therapies to treat diseases by harnessing the body's immune system.
- Ticker
- INMB:NASDAQ
- Asset type
- Stock
- Market cap
- $61.6M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
Inmune Bio Inc. INMB:NASDAQ stock context
This page tracks Inmune Bio Inc.'s INMB:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following INMB:NASDAQ. INMB:NASDAQ is the stock-level entry point for investors researching Inmune Bio Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Inmune Bio Inc. is a public company traded under the ticker INMB in the American market. The company has a market capitalization of approximately $43.1 million. Inmune Bio focuses on developing innovative therapies to treat diseases by harnessing the body's immune system.
Latest news from Inmune Bio Inc.
INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board
September 14, 2026
INmune Bio to Present at the H.C. Wainwright Global Investment Conference
September 9, 2026
INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings
August 26, 2026
INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress
August 6, 2026
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
July 31, 2026
Inmune Bio Inc. earnings calls
INmune Bio Inc. (INMB) Q2 2026 Earnings Call
August 6, 2026 · Replay with transcript and chapters
INmune Bio Inc. (INMB) Q1 2026 Earnings Call
May 7, 2026 · Replay with transcript and chapters
INmune Bio Inc. (INMB) Q4 2025 Earnings Call
March 30, 2026 · Replay with transcript and chapters
INmune Bio Inc. (INMB) Q3 2025 Earnings Call
October 30, 2025 · Replay with transcript and chapters
INmune Bio Inc. (INMB) Q2 2025 Earnings Call
August 7, 2025 · Replay with transcript and chapters
INmune Bio Inc. (INMB) Q1 2025 Earnings Call
May 8, 2025 · Replay with transcript and chapters
Research Inmune Bio Inc.
Inmune Bio Inc. investor report
Review AI stock analysis and investor report context for INMB:NASDAQ.
Inmune Bio Inc. company profile
View the public company page for Inmune Bio Inc. on 6ix.
Inmune Bio Inc. news
Read company news and market updates connected to Inmune Bio Inc..
Inmune Bio Inc. investor events
Find investor webinars, events, and replay context for Inmune Bio Inc..
Alternate listings
INMB:BOATS
US · USD
Alternate listing for Inmune Bio Inc.; the primary context on this page is INMB:NASDAQ.
A2PCBU:LS
DE · EUR
Alternate listing for Inmune Bio Inc.; the primary context on this page is INMB:NASDAQ.
0Y2:TRADEGATE
DE · EUR
Alternate listing for Inmune Bio Inc.; the primary context on this page is INMB:NASDAQ.